As of June 30, Soleno had cash and cash equivalents of approximately $19.4M, which includes $10M received during the quarter from the sale of warrants pursuant to the terms of the SPA. “We are eagerly awaiting top-line results from the fully-enrolled randomized withdrawal period of Study C602, which remain on track for the third quarter of 2023,” said Anish Bhatnagar, CEO of Soleno Therapeutics. “If successful, results have the potential to support a planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA). We continue to believe in the significant potential of DCCR as an effective and safe therapy for patients with PWS.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SLNO:
- SLNO Upcoming Earnings Report: What to Expect?
- Soleno Therapeutics to participate in a conference call with Cantor Fitzgerald
- Soleno Therapeutics files to sell 22.6M shares of common stock for holders
- Soleno Therapeutics management to meet virtually with Oppenheimer
- Soleno Therapeutics initiated with an Overweight at Cantor Fitzgerald